Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826505 | 1.00 | LMNA (0.39) | LMNATSHRNFKB1PMP22GSTK1 | |
| SCHEMBL825651 | 1.00 | LMNA (0.39) | LMNATSHRNFKB1PMP22GSTK1 | |
| SCHEMBL4310967 | 0.98 | GSTK1 (0.37) | LMNATSHRNFKB1PMP22GSTK1 | |
| SCHEMBL846234 | 0.79 | ALDH1A1 (0.47) | LMNATSHRNFKB1PMP22GSTK1 | |
| SCHEMBL17821007 | 0.79 | ALDH1A1 (0.47) | LMNATSHRNFKB1PMP22GSTK1 | |
| SCHEMBL30773222 | 0.77 | ALDH1A1 (0.49) | LMNATSHRNFKB1PMP22GSTK1 | |
| SCHEMBL9607 | 0.75 | KMT2A (0.43) | KMT2AALDH1A1 | |
| Octanedioate SCHEMBL7080168 | 0.73 | TSHR (0.55) | LMNATSHRNFKB1PMP22FFAR4 | |
| SCHEMBL15475975 | 0.72 | PTGS1 (0.45) | LMNAGSTK1PTGER4PTGER3PTGER2 | |
| SCHEMBL16460504 | 0.72 | ALDH1A1 (0.35) | LMNATSHRNFKB1PMP22GSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038427-A1 | CYCLIC NUCLEIC ACID MOLECULE HAVING GENE EXPRESSION CONTROL FUNCTION | BONAC CORPORATION (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3604528-A1 | CYCLIC NUCLEIC ACID MOLECULE HAVING GENE EXPRESSION CONTROL FUNCTION | Bonac Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| WO-2009066080-A2 | ARRAY | NANOBIODESIGN LIMITED (GB) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038427-A1 | CYCLIC NUCLEIC ACID MOLECULE HAVING GENE EXPRESSION CONTROL FUNCTION | RNMT, RNGTT, SRRT | LMNA 1101/4885TSHR 1664/4885NFKB1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.